Onsdag 28 Oktober | 18:10:22 Europe / Stockholm

Svenska | English

Evaxion

Beskrivning

Land	Danmark
Lista	78
Sektor	Hälsovård
Industri	Bioteknik

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-09-14 14:00:00 Evaxion applies its AI-Immunology™ platform in autoimmune diseases 3,07 USD | -1,92%

2026-08-20 13:30:00 Evaxion announces business update and second quarter 2026 financial results 3,28 USD | +4,13%

2026-08-17 14:00:00 Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program 3,13 USD | -6,29%

2026-08-14 14:00:00 Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 3,34 USD | +1,21%

2026-07-17 13:15:00 Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 3,08 USD | +1,82%

2026-07-12 15:30:00 Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

2026-07-01 14:00:00 Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 3,20 USD | +3,23%

2026-06-12 09:00:00 Evaxion receives Prix Galien UK Award for Best digital health solution 3,64 USD | +0,83%

2026-06-11 08:00:00 Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia 3,61 USD | -3,22%

2026-05-12 15:30:00 Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress 4,17 USD | -1,30%

2026-05-07 13:30:00 Evaxion announces business update and first quarter 2026 financial results 4,07 USD | -7,71%

2026-05-04 14:00:00 Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 4,57 USD | +1,56%

2026-04-27 14:00:00 Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer 4,18 USD | +1,46%

2026-04-17 21:10:00 Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial 4,45 USD | +7,49%

2026-04-17 21:00:00 New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma 4,45 USD | +7,49%

2026-04-16 17:30:00 Evaxion concludes Annual General Meeting 4,14 USD | 0,00%

2026-04-07 14:00:00 Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 3,80 USD | +1,60%

2026-03-30 14:00:00 Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress 3,78 USD | +7,39%

2026-03-19 14:00:00 Notice to convene Evaxion’s Annual General Meeting 4,00 USD | +5,82%

2026-03-17 21:30:00 Evaxion to present new data at AACR Annual Meeting 3,83 USD | +0,26%

2026-03-05 15:28:30 Evaxion announces business update and full year 2025 financial results 3,37 USD | +8,71%

2026-03-05 14:02:28 Evaxion plans to file 2025 annual report later today 3,37 USD | +8,71%

2026-03-02 14:00:00 Evaxion to announce business update and full year 2025 financial results on March 5, 2026 3,17 USD | +0,32%

2026-01-13 14:00:00 Evaxion expands AI-Immunology™ platform into autoimmune diseases 5,10 USD | -1,54%

2026-01-07 14:00:00 Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week 5,39 USD | +6,73%

2025-12-19 13:00:00 Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 4,70 USD | -18,26%

2025-12-06 20:00:00 Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

2025-11-20 14:00:00 Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 5,34 USD | +9,43%

2025-11-12 14:00:00 Evaxion announce 2026 financial calendar 6,04 USD | +0,67%

2025-11-07 23:10:00 Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 6,38 USD | +1,92%

2025-11-06 13:30:00 Evaxion announces business update and third quarter 2025 financial results 6,26 USD | +10,60%

2025-11-03 15:00:00 Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate 5,77 USD | +0,35%

2025-10-31 14:05:49 Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 5,75 USD | -0,17%

2025-10-31 13:00:00 Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 5,75 USD | -0,17%

2025-10-30 13:00:00 Evaxion raises $7.2 million, extending cash runway to second half of 2027 5,76 USD | +0,17%

2025-10-27 13:00:00 Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer 6,13 USD | +4,07%

2025-10-17 14:15:51 Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 6,79 USD | -29,27%

2025-10-13 14:00:02 Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 6,26 USD | +6,10%

2025-10-08 14:12:21 Evaxion expands AI-Immunology™ platform with automated vaccine design module 6,29 USD | +9,97%

2025-10-03 15:00:38 Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting 5,43 USD | +14,56%

2025-09-25 13:00:57 Evaxion out-licenses vaccine candidate EVX-B3 to MSD 4,53 USD | +37,27%

2025-08-27 14:00:47 Evaxion to present at several conferences during the second half of 2025 3,04 USD | -1,94%

2025-08-14 13:30:26 Evaxion announces business update and second quarter 2025 financial results 2,86 USD | -5,92%

2025-08-11 14:00:43 Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 2,77 USD | -2,12%

2025-07-25 15:00:04 Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 2,72 USD | +0,37%

2025-07-11 14:00:36 Evaxion finalizes agreement with EIB to convert debt into equity 2,66 USD | +3,10%

2025-07-01 14:30:29 Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio 2,48 USD | +1,22%

2025-06-25 14:00:38 Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus 2,59 USD | +5,71%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode